Bringing the Oncology Community Together
Giants of Cancer Care 2015
Targeted-Chemo Combination Active In Sarcomatoid, High-Risk RCC
A fourth of patients with sarcomatoid or poor-risk metastatic renal-cell carcinoma responded to treatment with the combination of sunitinib and gemcitabine.
Read More >>
Adding Anti-PD-L1 Antibody to Bevacizumab Induces Responses in mRCC
Sequencing VEGFR-Targeted and mTOR-Targeted Therapy in Advanced Renal Cell Carcinoma
Chronic Kidney Disease Associated With Increased Risk of Renal and Urothelial Cancers
Targeting Src Adds No Benefit in VEGF-Resistant Metastatic Renal Cell Carcinoma
Durable Responses Observed with Nivolumab in Previously Treated mRCC
Not Yet Ready for Prime Time: Lessons Learned From a Failed Molecular Marker–Based Lung Cancer Trial
View More >>
- A Network of Your Peers
View more >>
Dr. Haas on Adjuvant Sorafenib or Sunitinib for RCC
Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCC
Dr. McKay on Statin Use in Patients With mRCC
Most Popular Right Now
Tweets by @OncLive
Minimizing Toxicity While Maintaining Efficacy in RCC
Moderated by Robert A. Figlin, MD, this panel discussion includes expert perspectives from Daniel J. George, MD, Sumanta Kumar Pal, MD, Brian I. Rini, MD, and Nizar M. Tannir, MD.
Avastin (bevacizumab) Plus IFN in mRCC
Ronald Bukowski, MD, and Thomas Hutson, DO, PharmD, disucss bevacizumab in metastatic renal cell carcinoma.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.